Table 1 Patient Clinicopathological features of the two selected groups and the multivariate and univariate analysis in the TCGA dataset
Characteristics | ER+/PR-/HER2- | ER+/PR+/HER2- | p |
|---|---|---|---|
Age | |||
< 35 | 2 (3.3) | 11 (2.7) | 0.418 |
35–49 | 10 (16.7) | 97 (23.7) | |
50–69 | 31 (51.7) | 218 (53.3) | |
70+ | 17 (28.3) | 83 (20.3) | |
AJCC Stagea | 0.005 | ||
Stage I | 9 (15.0) | 83 (20.9) | |
Stage II | 27 (45.0) | 222 (55.8) | |
Stage III | 19 (31.7) | 86 (21.6) | |
Stage IV | 5 (8.3) | 7 (1.8) | |
Histology | 0.667 | ||
Infiltrating Ductal Carcinoma | 46 (76.7) | 316 (77.3) | |
Infiltrating Lobular Carcinoma | 6 (10.0) | 54 (13.2) | |
Mixed Histology | 4 (6.7) | 16 (3.9) | |
Others | 4 (6.7) | 23 (5.6) | |
PAM50 | < 0.001 | ||
Luminal A | 12 (27.9) | 181 (65.8) | |
Luminal B | 18 (41.9) | 81 (29.5) | |
Basal-like | 7 (16.3) | 3 (1.1) | |
HER2-enriched | 4 (9.3) | 6 (2.2) | |
Normal-like | 2 (4.7) | 4 (1.5) | |
Methylation Clusterb | < 0.001 | ||
Cluster 1 | 8 (13.3) | 80 (19.6) | |
Cluster 2 | 9 (15.0) | 124 (30.3) | |
Cluster 3 | 9 (15.0) | 40 (9.8) | |
Cluster 4 | 19 (31.7) | 149 (36.4) | |
Cluster 5 | 12 (20.0) | 16 (3.9) | |
NA | 3 (5.0) | 0 (0.0) | |
CN Clusterb | 0.001 | ||
Cluster 1 | 17 (30.4) | 42 (10.4) | |
Cluster 2 | 13 (23.2) | 161 (40.0) | |
Cluster 3 | 11 (19.6) | 73 (18.2) | |
Cluster 4 | 9 (16.1) | 71 (17.7) | |
Cluster 5 | 6 (10.7) | 55 (13.7) | |
miRNA Clusterb | 0.788 | ||
Cluster 1 | 4 (7.8) | 29 (7.8) | |
Cluster 2 | 8 (15.7) | 70 (18.8) | |
Cluster 3 | 4 (7.8) | 18 (4.8) | |
Cluster 4 | 13 (25.5) | 107 (28.7) | |
Cluster 5 | 7 (13.7) | 33 (8.8) | |
Cluster 6 | 9 (17.6) | 83 (22.3) | |
Cluster 7 | 6 (11.8) | 33 (8.8) | |